Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | PLAT | P00750 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | ARG1 | P05089 | 2/20 | 0.33 |
| ▸ | ARG2 | P78540 | 2/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.32 |
| ▸ | PEPD | P12955 | 1/20 | 0.32 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | TLR4 | O00206 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL5042547 | 1.00 | EPHX2 (0.42) | EPHX2CYP2D6PLGPLATLMNA | |
| Acetic Acid SCHEMBL2338205 | 1.00 | EPHX2 (0.42) | EPHX2CYP2D6PLGPLATLMNA | |
| Acetic Acid SCHEMBL5042448 | 0.88 | PLG (0.47) | EPHX2CYP2D6PLGPLATLMNA | |
| SCHEMBL12856273 | 0.88 | — | — | |
| SCHEMBL10053834 | 0.88 | — | — | |
| SCHEMBL10305556 | 0.88 | — | — | |
| SCHEMBL19090146 | 0.88 | — | — | |
| SCHEMBL715682 | 0.88 | — | — | |
| SCHEMBL19090147 | 0.88 | — | — | |
| SCHEMBL13579950 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008011016-A2 | TREATING GASTROESOPHAGEAL REFLUX DISEASE WITH 5-HT3- AND GABA RECEPTOR AGONISTS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | WO | claimed |
| US-20040248979-A1 | Method of treating lower urinary tract disorders | DYNOGEN PHARMACEUTICALS, INC. | 2004-12-09 | — | — | US | claimed |
| US-20110294881-A1 | METHODS FOR TREATING LOWER URINARY TRACT DISORDERS USING alpha2delta SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS | EDUSA PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20090203792-A1 | METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING ALPHA2DELTA SUBUNIT CALCIUM CHANNEL MODULATORS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20080275080-A1 | Methods for treating lower urinary tract disorders using alpha2delta subunit channel modulators with smooth muscle modulators | DYNOGEN PHARMACUETICALS, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080221039-A1 | Kinin Antagonists For Treating Bladder Dysfunction | JERINI AG (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20080085916-A1 | METHODS FOR TREATING LOWER URINARY TRACT DISORDERS USING ALPHA2DELTA SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2008-04-10 | — | — | US | disclosed |
| WO-2008011016-A2 | TREATING GASTROESOPHAGEAL REFLUX DISEASE WITH 5-HT3- AND GABA RECEPTOR AGONISTS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| EP-1202725-B1 | METHOD OF TREATING SYMPTOMS OF HORMONAL VARIATION, INCLUDING HOT FLASHES | UNIV ROCHESTER (US) | 2007-04-11 | — | — | EP | disclosed |
| US-20070060652-A1 | Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-20060276542-A1 | Methods for treating functional bowel disorders using alpha2 subunit calcium channel modulators with smooth muscle modulators | DYNOGEN PHARMACEUTICALS, INC. | 2006-12-07 | — | — | US | disclosed |
| US-20060188575-A1 | Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulators | DYNOGEN PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| EP-1621193-A2 | Treatment of non-painful bladder disorders using alpha2-delta-subunit calcium channel modulators | Dynogen Pharmaceuticals Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20050239890-A1 | Methods for decreasing detrusor muscle overactivity | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | US | disclosed |
| US-20050228049-A1 | Administering gabapentin, pregabalin, GABA analogs, fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds; treatment of overactive bladder without loss of urine | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-20050054725-A1 | Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulators | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | US | disclosed |
| US-20040248979-A1 | Method of treating lower urinary tract disorders | DYNOGEN PHARMACEUTICALS, INC. | 2004-12-09 | — | — | US | disclosed |
| US-20040198822-A1 | Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators | DYNOGEN PHARMACUETICALS, INC. (US) | 2004-10-07 | — | — | US | disclosed |
| US-20040142034-A1 | Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulators | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | US | disclosed |
| US-6310098-B1 | PROVIDING GAMMA-BUTYRIC ACID, SALT OR ANALOG WHICH BINDS AN ALPHA2DELTA SUBUNIT OF A VOLTAGE-GATED CALCIUM CHANNEL AND ADMINISTERING ABOVE COMPOUND TO A PATIENT EXPERIENCING HOT FLASHES | UNIVERSITY OF ROCHESTER | 2001-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248979-A1 | Method of treating lower urinary tract disorders | RYR2, CACNA1S, CACNA1D | EPHX2 2075/4885CYP2D6 2112/4885PLG 841/4885 |
| US-20040198822-A1 | Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators | GABRB2, GABRD, GABRB3 | EPHX2 2892/4885CYP2D6 1415/4885PLG 1223/4885 |
| US-20080221039-A1 | Kinin Antagonists For Treating Bladder Dysfunction | BDKRB2, BDKRB1, F2R | EPHX2 617/4885CYP2D6 1728/4885PLG 65/4885 |
| US-20070060652-A1 | Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators | GABRB2, GABRB3, GABRB1 | EPHX2 3033/4885CYP2D6 1726/4885PLG 1326/4885 |
| US-20080085916-A1 | METHODS FOR TREATING LOWER URINARY TRACT DISORDERS USING ALPHA2DELTA SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS | GABRB2, GABRB3, GABRB1 | EPHX2 3033/4885CYP2D6 1726/4885PLG 1326/4885 |
| US-20040142034-A1 | Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulators | CACNA1D, CACNA1B, GABRB2 | EPHX2 3186/4885CYP2D6 1378/4885PLG 2487/4885 |
| US-20080275080-A1 | Methods for treating lower urinary tract disorders using alpha2delta subunit channel modulators with smooth muscle modulators | GABRB2, GABRB3, GABRB1 | EPHX2 2717/4885CYP2D6 1581/4885PLG 1217/4885 |
| US-20050239890-A1 | Methods for decreasing detrusor muscle overactivity | GABRB2, GABRB3, GABRB1 | EPHX2 2891/4885CYP2D6 2455/4885PLG 899/4885 |
| US-20090203792-A1 | METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING ALPHA2DELTA SUBUNIT CALCIUM CHANNEL MODULATORS | GABRB2, CACNA1D, CACNA1B | EPHX2 2804/4885CYP2D6 1465/4885PLG 2355/4885 |
| US-20060276542-A1 | Methods for treating functional bowel disorders using alpha2 subunit calcium channel modulators with smooth muscle modulators | GABRB2, GABRB3, GABRB1 | EPHX2 2779/4885CYP2D6 2039/4885PLG 1985/4885 |
| US-20060188575-A1 | Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulators | GABRB2, CACNA1D, CACNA1B | EPHX2 2804/4885CYP2D6 1465/4885PLG 2355/4885 |
| US-20110294881-A1 | METHODS FOR TREATING LOWER URINARY TRACT DISORDERS USING alpha2delta SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS | GABRB2, GABRB3, GABRB1 | EPHX2 3033/4885CYP2D6 1726/4885PLG 1326/4885 |
| US-20050054725-A1 | Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulators | GABRB2, CACNA1D, CACNA1B | EPHX2 2804/4885CYP2D6 1465/4885PLG 2355/4885 |
| US-20050228049-A1 | Administering gabapentin, pregabalin, GABA analogs, fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds; treatment of overactive bladder without loss of urine | GABRB2, GABRB1, GABRB3 | EPHX2 3597/4885CYP2D6 1452/4885PLG 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.